Sato Yasushi, PhD | Asahikawa Medical University; Takewa Yoshiaki, MD, PhD; Inoue Yusuke, PhD; Terazawa Takeshi, PhD
Competition Sponsor: Japan Agency for Medical Research and Development
Awardee Year: 2024
Valvular heart disease is caused by congenital malformations or age-related tissue degeneration. Approximately 200 million patients worldwide are estimated to suffer from valvular diseases, and this number is expected to rise with the aging population. One treatment for severe cases is valve replacement surgery using artificial valves. However, current artificial valves, such as mechanical and bioprosthetic valves, have limitations in antithrombotic properties and durability, leading to a significant burden on patients. Biovalve represents a groundbreaking advancement in heart valve therapy, offering substantial benefits for both elderly and pediatric patients. Unlike conventional artificial valves, which require lifelong medication and have limited durability, Biovalve is created entirely from the patient’s tissue by simply subcutaneously implanting a mold. This method harnesses the body’s natural healing abilities to produce a personalized heart valve, avoiding risks such as immune rejection and toxicity.
For pediatric patients, Biovalve’s ability to grow and adapt with the child significantly reduces the need for multiple surgeries as they age. Similarly, for older patients, Biovalve’s durability and superior antithrombotic properties minimize the need for re-operations and hospital visits, enhancing quality of life and independence. By reducing ongoing medical interventions and associated risks, Biovalve promotes healthier, longer lives for patients of all ages. Research in large animals is underway to optimize the design and evaluate its function, with clinical trials planned once safety and efficacy are confirmed. Our goal is to validate Biovalve’s safety and effectiveness and bring this innovative solution to patients worldwide, ultimately transforming heart valve therapy.